<--- Back to Details
First PageDocument Content
Business / Economy / Health care / Gilead Sciences / Specialty drugs / Pharmaceuticals policy / Tenofovir alafenamide / Valeant Pharmaceuticals / Tenofovir disoproxil / Rilpivirine / Pharmaceutical industry in China / AstraZeneca
Date: 2016-03-30 10:03:18
Business
Economy
Health care
Gilead Sciences
Specialty drugs
Pharmaceuticals policy
Tenofovir alafenamide
Valeant Pharmaceuticals
Tenofovir disoproxil
Rilpivirine
Pharmaceutical industry in China
AstraZeneca

March 4, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. Sponsored By:

Add to Reading List

Source URL: www.dcat.org

Download Document from Source Website

File Size: 328,55 KB

Share Document on Facebook

Similar Documents

California Schools VEBA Important Benefit Update Attention Member IMPORTANT: If you have not received your Welcome Kit with your ID cards, please

California Schools VEBA Important Benefit Update Attention Member IMPORTANT: If you have not received your Welcome Kit with your ID cards, please

DocID: 1rr76 - View Document

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

February 2016 Rx Price Watch Report

February 2016 Rx Price Watch Report

DocID: 1rosR - View Document

présenteit - mediA - phA rmA

présenteit - mediA - phA rmA

DocID: 1riP0 - View Document

PDF Document

DocID: 1ri6p - View Document